Does ZIOPHARM Oncology Inc. (ZIOP) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

ZIOPHARM Oncology Inc. (ZIOP) is around the middle of the Biotechnology industry according to InvestorsObserver. ZIOP received an overall rating of 53, which means that it scores higher than 53 percent of all stocks. ZIOPHARM Oncology Inc. also achieved a score of 42 in the Biotechnology industry, putting it above 42 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 53 means the stock is more attractive than 53 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

ZIOPHARM Oncology Inc. (ZIOP) stock has fallen -0.93% while the S&P 500 is up 0.1% as of 10:32 AM on Tuesday, Jun 30. ZIOP is down -$0.03 from the previous closing price of $3.21 on volume of 262,479 shares. Over the past year the S&P 500 is up 3.11% while ZIOP is down -42.29%. ZIOP lost -$0.70 per share the over the last 12 months.

To screen for more stocks like ZIOP click here.

Here is the original post:
Does ZIOPHARM Oncology Inc. (ZIOP) Stock Beat its Rivals in Biotechnology? - InvestorsObserver